Does dupilumab alter blood glucose levels?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 26, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Dupilumab NO altera significativamente la glicemia en la mayoría de los pacientes

Dupilumab no tiene efectos conocidos sobre la glucemia según la información de la FDA y las guías clínicas principales, aunque existen reportes de casos aislados de diabetes mellitus asociada al medicamento 1.

Evidencia de Seguridad Principal

La información oficial de la FDA sobre dupilumab no menciona alteraciones de la glucemia entre sus efectos adversos conocidos 1. Los estudios de seguridad más amplios, que incluyen más de 7000 pacientes-año de uso de dupilumab en dermatitis atópica, no reportan hiperglucemia o diabetes como eventos adversos significativos 2.

Efectos Adversos Documentados

Los efectos adversos más prevalentes de dupilumab son:

  • Trastornos oculares de superficie (6-26% de pacientes): conjuntivitis, ojo seco 3
  • Reacciones en el sitio de inyección
  • NO se menciona alteración de glucemia en los perfiles de seguridad establecidos 1, 2

Casos Aislados Reportados

Advertencia Importante: Reportes Excepcionales

Existen solo dos casos documentados en la literatura de diabetes mellitus asociada a dupilumab:

  1. Primer caso (2022): Mujer de 18 años con predisposición genética (HLA positivo para diabetes tipo 1) que desarrolló diabetes tipo 1 a los 7 meses de tratamiento 4

  2. Segundo caso (2024): Hombre de 66 años SIN predisposición genética que desarrolló hiperglucemia, con resolución completa tras suspender dupilumab 5

Mecanismo Teórico Propuesto

El dupilumab bloquea IL-4 e IL-13 (citoquinas Th2), lo que podría causar un predominio relativo de Th1, potencialmente acelerando diabetes tipo 1 en individuos genéticamente susceptibles 4. Sin embargo, esto es puramente especulativo basado en dos casos.

Recomendación Práctica

No es necesario monitorear rutinariamente la glucemia en pacientes que inician dupilumab, ya que:

  • No está listado como efecto adverso en la información de la FDA 1
  • Los estudios de seguridad extensos no lo identifican como problema 2
  • Solo existen 2 casos reportados entre cientos de miles de pacientes tratados

Situaciones que Requieren Vigilancia

Considere monitoreo de glucemia si el paciente presenta:

  • Síntomas de hiperglucemia: poliuria, polidipsia, pérdida de peso inexplicable
  • Antecedentes familiares fuertes de diabetes tipo 1
  • HLA positivo para diabetes tipo 1 (si se conoce)

En estos casos raros, si se desarrolla hiperglucemia:

  • Suspender dupilumab inmediatamente
  • Iniciar manejo con insulina según necesidad
  • La hiperglucemia puede ser reversible tras suspensión del medicamento 5

References

Related Questions

Can performing 100 repetitions of moderate-to-heavy resistance exercises on large muscle groups every other day for 15 minutes improve insulin sensitivity and help manage pre-diabetes?
For a 19‑year‑old with type 1 diabetes, weight 86 kg, creatinine 0.74 mg/dL, GFR > 90 mL/min, bicarbonate 17 mmol/L, anion gap 13, currently on metformin 750 mg daily and insulin glargine (Lantus) 15 U at 8 am and 35 U at 8 pm with carbohydrate‑to‑insulin ratios of 1 U per 6 g carbs at breakfast and 1 U per 7 g carbs at lunch/dinner and an insulin‑sensitivity factor of 25 mg/dL per U, and blood glucose values of 184 mg/dL (8 am), 220 mg/dL (noon), 262 mg/dL (5 pm), 237 mg/dL (10 pm), and 97 mg/dL (4 am), what should the morning and evening Lantus doses be and what should the insulin‑sensitivity factor and insulin‑to‑carbohydrate ratios be adjusted to?
For a 19‑year‑old patient with type 1 diabetes weighing 86.2 kg who is currently taking insulin glargine (Lantus) 12 U at 08:00 and 35 U at 20:00 and uses insulin‑to‑carbohydrate ratios of 1 U per 5 g carbs for breakfast and lunch and 1 U per 6 g carbs for dinner, what should the basal Lantus dose and insulin‑to‑carbohydrate ratio be adjusted to?
What is the clinical significance of a +1 glucose result on a urine dipstick and how should it be evaluated?
During a 100‑gram oral glucose tolerance test, my 180‑minute glucose level was 39 mg/dL, yet my home glucose measurements are within normal limits—what does this finding indicate and how should it be managed?
In an adult female with an uncomplicated urinary tract infection who did not respond to nitrofurantoin, should I prescribe levofloxacin (Levaquin) or cefalexin (Keflex)?
What dose of Adderall immediate-release (mixed amphetamine salts) can be given to a patient currently taking Vyvanse (lisdexamfetamine) 40 mg daily?
How should I manage a patient with elevated alanine aminotransferase (ALT) and creatine kinase (CK)?
Does the patient need a supplemental (booster) stimulant in addition to lisdexamfetamine (Vyvanse) 40 mg daily?
Is dupilumab associated with erectile dysfunction?
What is the recommended dosage range for Vyvanse (lisdexamfetamine) in patients aged 6 years and older, including adolescents and adults?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.